CD274 and neoplasm: The selection of first-line systemic anticancer therapy for unresectable advanced NSCLC is guided by a multifaceted assessment of different tumor features, including histology, PD-L1 expression and conquering actionable molecular alterations, along with patient-related factors such as PS-ECOG and comorbidities, together with individual preferences [4].